AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 261 min read$TWST

Leproust Emily M. sold $367K of TWST

Leproust Emily M. (Chief Executive Officer) sold 6,888 shares of Twist Bioscience Corp (TWST) at $53.26 ($0.37M total) on 2026-05-21.

Original reporting
SEC EDGAR · Leproust Emily M.
Published May 26, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates insider ownership levels but does not include any company-specific operational, financial, or regulatory development.

02

Market read

Traders may monitor for sentiment/positioning effects, but there is no direct catalyst to drive a fundamental repricing.

03

What to watch

The article lacks context on whether the sale was planned for liquidity, tax, or diversification; also no change in company guidance or fundamentals is provided.

Relevance 6/10Timing: Immediate awareness for positioning/flow; not a scheduled catalyst.

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience CEO Emily M. Leproust filed an open-market sale of 6,888 shares for about $366.8K, reducing direct holdings to 846,872.

Expected impact

Near-term impact likely limited; any move would be more sentiment/flow-driven than catalyst-driven.

Evidence & confidence

Form 4 insider transactions (especially open-market sales) often reflect diversification or liquidity needs; the filing provides no operational or financial update.

Market effects

Sector

Minimal; single-company insider sale typically does not reset biotech/biomanufacturing read-throughs.

Regional

None indicated; filing is US SEC disclosure only.

Global

None indicated; no international deal/regulatory development mentioned.

Counterpoint

What could challenge this read

Insider selling under a non-10b5-1 plan can still be routine diversification; without accompanying negative news, price reaction may be overstated.

Key entities

  • issuer
    Twist Bioscience Corp

    Subject of the Form 4 insider sale by CEO Emily M. Leproust.

  • insider
    Emily M. Leproust

    CEO and officer/director who sold 6,888 shares on 2026-05-21 at $53.2570/share.

Read at source← All news

Related articles

AUG 5
$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

rttnews.com3 min
AUG 4
$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

yahoo.com6 min
AUG 3
$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

investing.com3 min
AUG 3
$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

SEC EDGAR 8-K4 min
MAY 27
$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.

benzinga.com4 min